PharmaCyte Biotech (PMCB) Stock Slumps 70% YTD: Will it Rebound?
PharmaCyte Biotech (NASDAQ:PMCB), a company that produces cellular therapies for cancer and diabetes patients, is moving fast and thus a potential buy for the investors. Recently in July the company has announced of enacting a 1-for-1,500 reverse stock split for its common stock which gained effectiveness on the OTCQB Exchange at the opening of the market on July 12. This resulted in the decline the number of outstanding common stock…